Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells featuring CellChorus and Indee Labs
Researchers from Indee Labs, CellChorus, the Gladstone-UCSF Institute of Genomic Immunology, the UCSF Helen Diller Family Comprehensive Cancer Center and Institute for Human Genetics (IHG), the Parker Institute for Cancer Immunotherapy, and the Medical University of South Carolina, published in Nature Scientific Reports this week showing that Indee Labs’ scaled-up hydroporation technology can process 5 × 10^8 cells in less than 10 seconds, showcasing the platform as a viable solution for high-yield CAR-T manufacturing with the potential for improved therapeutic outcomes. The paper included data from CellChorus showing that hydroporated cells had lower activation-induced cell death (death after contact with a tumor cell) and improved motility (the speed at which CAR-T cells migrated to subsequent target cells after being activated and forming synapses with target cancer cells) with non-inferior contact dynamics and potency compared to nucleofection.
